Core Viewpoint - The company Sunflower announced that its subsidiary, Beid Pharmaceutical, is participating in the continuation procurement of drugs from the national organized procurement batches 1-8, with some products expected to be selected [1] Group 1: Selected Products - The products expected to be selected include Clarithromycin tablets and Simvastatin tablets [1] - The procurement period for the selected products will last from the actual execution date of the selection results until December 31, 2028 [1] Group 2: Financial Impact - The sales revenue for Clarithromycin tablets in 2024 is projected to be 37.18 million yuan, accounting for 11.29% of the company's main business income during the same period [1] - The sales revenue for Simvastatin tablets is expected to be 1.71 million yuan, representing 0.52% of the company's main business income for the same period [1]

Core Viewpoint - Moderna shares experienced a 14% decline in Frankfurt following the U.S. FDA's refusal to review the company's influenza vaccine approval application [1] Company Summary - Moderna's stock opened 14% lower in Frankfurt, indicating a significant market reaction to the FDA's decision [1] - The trading volume was low, suggesting limited investor activity during this period [1] Industry Summary - The refusal by the U.S. FDA to review the influenza vaccine application may impact the broader vaccine market and investor sentiment towards vaccine developers [1]

Company Overview - Compass is a leading global contract caterer, serving 5.5 billion meals annually across more than 25 countries, and is recognized as a well-managed business [2] - The company derives approximately 75% of its revenues in U.S. dollars, highlighting its international operations [4] Currency Change Announcement - Compass announced it will change the currency of its share trading from sterling to U.S. dollars effective April 1, 2024, to align its trading currency with its reporting currency, thereby reducing foreign exchange volatility [1] - This move is part of a broader trend among British companies, with many now reporting in currencies other than sterling [8] Industry Context - The change in trading currency follows a recent adjustment in FTSE Russell's membership rules, allowing companies trading in dollars or euros to be considered for inclusion in the FTSE U.K. Index Series [5] - Other major companies, such as InterContinental Hotels Group, have also adopted this practice, indicating a shift in how British firms operate in global markets [6] Historical Perspective - The trend of companies reporting in foreign currencies is not new, with major firms like HSBC, AstraZeneca, and Shell having transitioned to dollar reporting in recent years [8][11] - Historically, Avis Europe was an early adopter of non-sterling reporting, having faced challenges in the past when attempting to report in the European Currency Unit [9][10] Market Reactions - The announcement from Compass has sparked discussions about the potential for more U.K. companies to follow suit and possibly list on the New York Stock Exchange, reflecting a growing trend of British firms seeking to align with global financial practices [4][13]

Eli Lilly has won Chinese regulators' approval for its drug to treat chronic inflammatory bowel disease, expanding the treatment's use to the world's second-largest pharmaceutical market, it said on W... ...

OneSource Specialty Pharma has received Saudi Food and Drug Authority (SFDA) approval for its generic Ozempic (semaglutide) in Saudi Arabia, paving the way for its commercialisation with Hikma Pharmaceuticals PLC (Hikma), their exclusive partner for the Middle East and North Africa (MENA), the company said.The approval marks OneSource’s entry—a contract development and manufacturing organisation—into Saudi Arabia, one of the largest markets for GLP-1 therapies. The partnership aims to increase access to aff ...

Group 1 - The core point of the article is the unexpected resignation of CSL's CEO Paul McKenzie, with Gordon Neller appointed as interim CEO just before the release of the company's half-year earnings for FY2026, leading to a significant drop in stock price and raising concerns about the company's strategic direction and acquisition valuations [1][2]. - CSL's stock price has been in a downward trend since August of the previous year, primarily due to the announcement of the Seqirus spin-off plan and subsequent downsizing of the R&D team, which led to doubts about the company's decision-making capabilities [2]. - The company is also burdened by a costly acquisition of Vifor for $11.7 billion in 2022, which has faced scrutiny regarding its return on investment and has contributed to operational challenges [2]. Group 2 - Gordon Neller, the new interim CEO, has extensive experience within CSL, having worked for 33 years in various roles, including CFO and president of Seqirus, and is well-acquainted with the company's core business areas [3]. - Neller has been granted full authority by the board to implement necessary reforms, emphasizing that his interim position does not imply a lack of action [3]. - Neller's compensation as interim CEO includes an annual fixed salary of approximately $2 million and a one-time stock award of $4 million, although he will not receive short-term or long-term incentives due to the lack of a fixed term for his position [3].

Core Viewpoint - Nasus Pharma Ltd. has announced a private placement of ordinary shares and warrants, aiming to raise approximately $15.0 million to support its clinical development efforts and other corporate purposes [1][5]. Group 1: Private Placement Details - The private placement involves the sale of 2,695,425 ordinary shares and accompanying warrants, priced at $5.565 per share and warrant [3]. - The warrants will have an exercise price of $6.53 per share, are immediately exercisable, and will expire two years from issuance or 30 trading days after the announcement of NS002 pivotal study results [4]. - Citizens Capital Markets is the lead placement agent, with Laidlaw & Company (UK) Ltd. as the co-placement agent [2]. Group 2: Use of Proceeds - The net proceeds from the private placement will be used to advance the pivotal clinical development of NS002 for anaphylaxis treatment, initiate first-in-human studies for other products, and for working capital and general corporate purposes [5]. Group 3: Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal products, particularly NS002, which is designed as a needle-free alternative for anaphylaxis treatment [8]. - The company's proprietary powder-based intranasal technology aims for rapid and reliable drug delivery, leveraging the nasal cavity's vascular network for quick absorption [8].

FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on February 10, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-5089826 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 401 ...

Core Viewpoint - Johnson & Johnson is positioned as a stable investment option amidst the volatility of high-growth AI stocks, with a notable 53% increase in share price over the past year, suggesting strong performance and potential for long-term income seekers [2][9]. Financial Performance - Johnson & Johnson's market capitalization stands at $575 billion, with a current share price of $238.32 and a dividend yield of 2.15% [7][5]. - The company has maintained a gross margin of 75.27%, indicating robust profitability [7]. Challenges and Risks - The company faces challenges such as government-led drug price negotiations affecting sales, particularly for certain medicines [4]. - Patent cliffs pose a risk, with the loss of exclusivity for the immunology drug Stelara leading to competition from biosimilars [4]. - Johnson & Johnson is also dealing with ongoing lawsuits related to its talc-based products, which could impact its reputation and financial standing [5]. Business Resilience - Johnson & Johnson's diverse portfolio across various therapeutic areas helps mitigate risks from competition and declining sales in specific products [7]. - The company is close to launching a robotic-assisted surgery device, which is expected to create additional growth opportunities [8]. - A strong balance sheet with the highest credit rating available positions the company well to navigate legal challenges and market fluctuations [8]. Dividend History - Johnson & Johnson is recognized as a "Dividend King," having increased its dividends for 63 consecutive years, making it an attractive option for income-focused investors [9].

Core Insights - Gilead Sciences reported $7.93 billion in revenue for Q4 2025, a year-over-year increase of 4.7% and a surprise of +4.63% over the Zacks Consensus Estimate of $7.57 billion [1] - The EPS for the same period was $1.86, slightly down from $1.90 a year ago, with an EPS surprise of +1.91% compared to the consensus estimate of $1.83 [1] Financial Performance - Total product sales in the U.S. reached $5.87 billion, exceeding the average estimate of $5.59 billion, representing a year-over-year change of +5.8% [4] - Total product sales globally were reported at $7.9 billion, surpassing the six-analyst average estimate of $7.53 billion, with a year-over-year change of +4.9% [4] - Royalty contract and other revenues were $22 million, below the average estimate of $38.66 million, reflecting a year-over-year decline of -33.3% [4] Product Sales Breakdown - Product sales for Liver Disease (Other) in the U.S. were $168 million, significantly above the average estimate of $141.36 million, marking a year-over-year increase of +189.7% [4] - Sales for HIV product Biktarvy totaled $3.97 billion, exceeding the average estimate of $3.79 billion, with a year-over-year change of +5.1% [4] - Sales for Veklury were $212 million, below the average estimate of $266.85 million, indicating a year-over-year decline of -37.1% [4] Stock Performance - Gilead's shares have returned +23.7% over the past month, while the Zacks S&P 500 composite showed no change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]